Caris Life Sciences
6655 North MacArthur Boulevard
Tel: 214-277-8700 or 800-979-8292
199 articles with Caris Life Sciences
Caris Life Sciences Raises $310 Million in Growth Capital from a Broad Syndicate of Leading Investors
The financing includes a $235 million equity investment co-led by Highland Capital Management and Coatue; Sixth Street participates in equity round and provides $75 million in debt financing
Molecular science company Caris Life Sciences secured $310 million in growth capital that will be used to expand its presence in precision medicine in oncology.
Caris' collaborative network focused on expanding the application of precision medicine in oncology supports Winship's enterprising approach to research leading to transformative discoveries in cancer care and treatment
Caris Life Sciences Launches CODEai - Real-World Clinico-Genomic Data Platform Powered by Artificial Intelligence
The most comprehensive data solution in the industry, comprised of over 215,000 cases of real-world patient records with integrated molecular and clinical outcomes data, offers an unmatched resource for developing a better understanding of the unique molecular mechanisms of cancer
Caris Life Sciences Appoints Brian Lamon, Ph.D., as Chief Business Officer, Head of BioPharma Business Development
Lamon to oversee business development strategy and execution, and brings over 15 years of pharmaceutical and academia experience to the company
Caris' collaborative network focused on expanding the application of precision medicine in oncology welcomes New England's largest medical oncology group
Dallas-based UT Southwestern Medical Center's Simmons Cancer Center, one of the elite centers in the country for patient care, research and education joins Caris' best-in-class collaborative research network focused on expanding the application of precision medicine in oncology
Additional research will highlight findings in colorectal and gastrointestinal cancers that could impact treatment decisions for patients
Caris Life Sciences Announces Participation in the 18th Annual Morgan Stanley Global Healthcare Conference
Brian J. Brille to present a fireside chat covering molecular science and precision medicine.
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced that Penn State Cancer Institute has joined its Precision Oncology Alliance™.
Caris Life Sciences Partners with Elevation Oncology to Advance Enrollment in Phase 2 Trial of Patients with Solid Tumors Harboring NRG1 Gene Fusions
Partnership explores innovative models for real-time identification, patient referral and enrollment of patients with solid tumors with a rare gene fusion
Montefiore Health System becomes the 39th member of the Caris collaborative network focused on expanding the application of precision medicine in oncology
Caris Life Sciences Showcases Data on KRAS Mutations in Patients With Non-Small Cell Lung and Pancreatic Cancer at ASCO20 Virtual Scientific Program
The combination of DNA sequencing and whole transcriptome sequencing provides critical insights that can guide treatment decisions across a range of cancers
New Jersey's only NCI-designated Comprehensive Cancer Center becomes the 37th member of Caris' collaborative network focused on expanding the application of precision medicine in cancer treatment
Caris Life Sciences to Present Data Spotlighting Clinical Impact of Precision Medicine in ASCO20 Virtual Scientific Program
Data from 14 studies to highlight role of company's portfolio of precision medicine technologies in guiding treatment decisions for patients with cancer across tumor types
Caris Life Sciences Submits Two PMA Applications to the FDA for Whole Exome and Whole Transcriptome Sequencing
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced the submission of two Pre-Market Approval applications for MI Exome™ CDx and MI Transcriptome™ CDx to the U.S. Food and Drug Administration.
The most comprehensive suite of molecular testing in the industry includes a new whole exome sequencing (DNA) assay complementing the Company's breakthrough whole transcriptome sequencing (RNA) performed on every patient
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced Chadi Nabhan, MD, MBA, FACP has been appointed Chairman of its Precision Oncology Alliance™.
Caris Life Sciences Launches MI FOLFOXai, Improving Overall Survival by 50% for Metastatic Colorectal Cancer Patients
First AI-powered FOLFOX predictor to guide first-line metastatic colorectal cancer treatment
IRVING, Texas , Feb. 19, 2020 /PRNewswire/ -- Caris Life Sciences ® , a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that Brian Brille , Vice Chairman of the Company, will present at the Cowen and Company 40 th Annual Health Care Conference on Tuesday, March 3, 2020 , at 9:30 a.m. Eastern time . The confe